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A B S T R A C T
Background
Many palliative care patients have reduced oral intake during their illness. The management of this can include the provision of
medically assisted hydration with the aim of prolonging the life of a patient, improving their quality of life, or both. This is an updated
version of the original Cochrane review published in Issue 2, 2008, and updated in February 2011.
Objectives
To determine the effect of medically assisted hydration in palliative care patients on their quality and length of life.
Search methods
We identified studies by searching the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, CINAHL,
CANCERLIT, Caresearch, Dissertation abstracts, SCIENCE CITATION INDEX and the reference lists of all eligible studies, key
textbooks and previous systematic reviews. The date of the latest search conducted on CENTRAL, MEDLINE and EMBASE was
March 2014.
Selection criteria
All relevant randomised controlled trials (RCTs) or prospective controlled studies of medically assisted hydration in palliative care
patients.
Data collection and analysis
We identified six relevant studies for this update. These included three RCTs (222 participants), and three prospective controlled trials
(360 participants). Two review authors independently assessed the studies for quality and validity. The small number of studies and
the heterogeneity of the data meant that a quantitative analysis was not possible, so we included a description of the main findings.
Main results
One study found that sedation and myoclonus (involuntary contractions of muscles) scores were improved more in the intervention
group. Another study found that dehydration was significantly higher in the non-hydration group, but that some fluid retention
symptoms (pleural effusion, peripheral oedema and ascites) were significantly higher in the hydration group. The other four studies
(including the three RCTs) did not show significant differences in outcomes between the two groups. The only study that had survival
as an outcome found no difference in survival between the hydration and control arms.
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Authors’ conclusions
Since the last version of this review, we found one new study. The studies published do not show a significant benefit in the use
of medically assisted hydration in palliative care patients; however, there are insufficient good-quality studies to inform definitive
recommendations for practice with regard to the use of medically assisted hydration in palliative care patients.
P L A I N L A N G U A G E S U M M A R Y
Medically assisted hydration to assist palliative care patients
Background
It is common for palliative care patients to have reduced fluid intake during their illness. Management of this condition includes
discussion with the patient, family and staff involved, and may include the provision of fluids with medical assistance. This can be
performed using a small plastic tube inserted into a vein or under the skin, or via a tube inserted into the stomach. It is unknown
whether this treatment helps people to feel better or live longer.
Study characteristics
We searched the international literature for randomised controlled trials looking at the effects of medically assisted hydration in adults
receiving palliative care. Randomised controlled trials allocate patients to one of two or more treatment groups in a random manner
and provide the most accurate information on the best treatment. We conducted the searches in April 2013 and March 2014.
Key results and quality of evidence
We found only six studies looking at this issue. The studies did not show a significant benefit in the use of medically assisted hydration
in palliative care patients; however, there are insufficient good-quality studies to make any definitive recommendations. . As a result, it
is not possible to define the benefits and harms of this treatment clearly.
B A C K G R O U N D
This review is an update of a previously published review in the
Cochrane Database of Systematic Reviews (Issue 2, 2008) on “Med-
ically assisted hydration for adult palliative care patients” (Good
2008).
Description of the condition
Many palliative care patients have a reduced oral intake during
their illness. The cause of this varies, but may be due partly to
a physical obstruction, anorexia/cachexia syndrome, generalised
weakness, bowel obstruction, nausea, decreased level of conscious-
ness, loss of desire to drink or no specific cause may be identified.
The most common time for this decreased oral intake is during
the terminal phase, when the patient becomes less conscious and,
therefore, less able to receive fluids orally (Morita 1998).
Description of the intervention
Management of this condition includes discussion with the pa-
tient, family and staff involved, and either no medical interven-
tion (but continued attention to treating any symptomatic prob-
lems, including good mouth care) or the provision of hydration
with medical assistance. Medically assisted hydration is usually
performed via the intravenous or subcutaneous routes (parenteral),
but can also use the gastrointestinal system (enteral). There is
great variation in practice with regards to hydration. For example,
Lanuke 2003 found that the rate of provision of medically assisted
hydration differed greatly across Canada (range 0% to 100%).
How the intervention might work
The aim of medically assisted hydration can be to prolong the
length of life of a patient, improve their quality of life (QoL), or
both. These benefits may come via the reversal of the physiological
factors associated with the patient’s decline. Balanced against these
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potential benefits are adverse events that can be associated with
any intervention (infection, bleeding, pain, etc.) (Bozzetti 1996).
Why it is important to do this review
There is controversy about the ethical aspects of medically assisted
hydration (Casarett 2005). The first ethical controversy centres on
whethermedically assisted hydration is a medical intervention or a
basic provision of comfort. Second, there is controversy as to how
and by whom decisions should be made with regards to medically
assisted hydration in patients who no longer have the capacity
to make decisions for themselves. This review will concentrate
on assessing the benefit of provision of hydration with medical
assistance versus the harm caused by such intervention in palliative
care patients. It is only with this information that clinicians and
patients can make informed decisions about whether this type of
intervention is beneficial or harmful to an individual patient.
There is a separate review considering medically assisted nutrition
for palliative care patients (Good 2014).
O B J E C T I V E S
Todetermine the effect ofmedically assisted hydration in palliative
care patients on their QoL and length of life.
M E T H O D S
Criteria for considering studies for this review
Types of studies
All relevant randomised controlled trials (RCTs) or prospective
controlled studies that fulfilled the inclusion criteria.
Types of participants
Participants included:
• palliative care participants who received medically assisted
hydration;
• patients receiving palliative care (WHO 2005);
• (but were not limited to) incurable cancer, dementia,
neurodegenerative diseases (e.g. motor neuron disease), human
immunodeficiency virus, chronic airways limitation and chronic
heart failure;
• whose prognosis was limited and the focus of care was QoL
(Doyle 2004); and
• adults aged 18 years and above, both male and female and
in any setting such as home, hospice or hospital.
We did not limit included participants to those in the terminal
phase of their illness. We excluded participants who were having
medically assisted hydration as part of a perioperative, chemother-
apy or radiotherapy regimen, or because of chemotherapy or ra-
diotherapy adverse effects.
Types of interventions
Medically assisted administration of fluids
• Medically assisted hydration - administration of non-
nutritional fluids, administered via the subcutaneous tissue,
venous system or enterally (nasogastric tube, jejunostomy,
gastrostomy).
Comparisons
• Placebo.
• No intervention.
• Usual treatment or supportive care.
Types of outcome measures
Primary outcomes
1. QoL on any measure (including symptom assessment
scales).
Secondary outcomes
1. Survival.
2. Adverse events.
Search methods for identification of studies
Electronic searches
We searched the following electronic databases using a search strat-
egy developed for MEDLINE via Ovid, but were modified appro-
priately for each database. See Appendix 1 for the search strategies.
• Cochrane Central Register of Controlled Trials
(CENTRAL) (searched up to Issue 2, 2014).
• MEDLINE (Ovid) (1966 to 25/03/2014).
• EMBASE (Ovid) (1980 to 25/03/2014).
• SCIENCE CITATION INDEX (ISI Web of Science)
(1900 to March 2014).
• CINAHL (EBSCO) (1982 to March 2014).
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• CANCERLIT (up to February 2008).
• Caresearch - database listing conference proceedings and
grey literature (up to February 2008).
• Dissertation abstracts (up to February 2008).
Searching other resources
Reference lists
We searched the reference lists of all eligible studies, key textbooks
and previous systematic reviews for additional studies.
Language
The search attempted to identify all relevant studies irrespective
of language. We found no non-English papers.
Data collection and analysis
Selection of studies
The original search was performed in October 2006, and repeated
in February 2008. A further search was performed in November
2010 for the first update. The original review included five studies,
with no new studies added for the first update. We performed
subsequent searches in April 2013 andMarch 2014 for the update
of this review (see Figure 1). From this search, we reviewed the
titles and abstracts and retrieved publications of eight studies in
full. After review of these articles, seven did not meet the inclusion
criteria, leaving one new study for inclusion (in addition to the
five studies from original review and update).
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Figure 1. Study flow diagram.
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Data extraction and management
Data extraction
We obtained the following information for each study:
1. study methods (study design, allocation, blinding, setting,
inclusion criteria);
2. participants (sample size, exclusions/inclusions, number,
disease, duration of study, withdrawals and drop-outs, site - e.g.
hospital, hospice, home);
3. intervention (type, route of delivery, control used);
4. outcome (QoL, symptom measures, survival, time from
death intervention was initiated); and
5. adverse effects.
All review authors extracted this information independently, and
agreed the final data by consensus.
Data analysis
We planned to pool results had there been sufficient data and
homogeneity between studies. However, we identified only three
RCTs, and only a small number of participants were recruited to
these studies. The heterogeneity of the data meant that a quanti-
tative analysis was not possible. A description of the main findings
from the studies is presented in the Results section.
Assessment of risk of bias in included studies
Quality
We assessed the methodological quality of the six studies.
Assessment of risk of bias in included studies
For this update, we continued to assess quality using the Oxford
Quality Scale (Jadad 1996), which allocates points for randomisa-
tion, blinding and the recording of study withdrawals. This scale
uses the following questions to rate the likelihood of bias (the
higher the score the less likelihood of bias, scale of zero to five).
1. Was the study described as randomised (one = yes; zero =
no)?
2. Was the study described as double blind (one = yes; zero =
no)?
3. Was there a description of withdrawals and drop-outs (one
= yes; zero = no)?
4. Was the method of randomisation well described and
appropriate (one = yes; zero = no)?
5. Was the method of double-blinding well described and
appropriate (one = yes; zero = no)?
6. Deduct one point each if methods for randomisation and
blinding were inappropriate.
Scoring system: maximum score = five; minimum score = zero.
The maximum possible score (indicating a trial of high method-
ological quality) is five.
Three studies were prospective controlled trials and their method-
ology was assessed using a scale devised by Rinck et al. (Rinck
1997).
1. Quality criteria - accrual of the study population.
2. Homogeneity and participant characteristics.
3. Randomisation.
4. Attrition and sample size.
5. Interventions.
6. Outcome measurement.
7. Presentation of results.
Score one point if criteria fully applied.
Score 0.5 point if criteria was not fully applied.
Score zero if criteria (mostly) not applied.
Scoring system: maximum score = seven, minimum score = zero.
For this update, we also used the Cochrane ’Risk of bias’ tool. We
completed a ’Risk of bias’ table for each included study, using the
criteria outlined in the Cochrane Handbook for Systematic Reviews
of Interventions (Higgins 2011).
We assessed the following for each study:
1. Random sequence generation (checking for selection bias).
2. Allocation concealment (checking for selection bias).
3. Blinding of participants and personnel (checking for
performance bias).
4. Blinding of outcome assessment (checking for detection
bias).
5. Incomplete outcome data (checking for attrition bias).
6. Selective reporting (checking for reporting bias).
7. Size of study (checking for possible biases confounded by
small size). We assessed studies as being at low risk of bias (≥
200 participants per treatment arm); unclear risk of bias (50 to
199 participants per treatment arm); high risk of bias (< 50
participants per treatment arm).
The results for each included study are reported in the
Characteristics of included studies table.
R E S U L T S
Description of studies
The searches for this update were run in April 2013 and March
2014, which identified one new RCT (Bruera 2013, 129 partici-
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pants) (see Figure 1 for details of the study selection process). In
addition to this new study were the original five studies in which
two were RCTs (Bruera 2005, 51 participants; Cerchietti 2000, 42
participants), and three were prospective controlled trials (Morita
2005, 226 participants; Waller 1994, 68 participants; Viola 1997,
66 participants). For the original search, seven studies appeared to
meet the inclusion criteria (Bruera 2005; Cerchietti 2000; Morita
2002; Morita 2005; Morita 2006; Waller 1994; Viola 1997). On
further review, two studies were excluded (Morita 2002; Morita
2006). One study was excluded because there were no compar-
isons between the groups with regards to hydration (Morita 2002).
The second study was excluded because there was no comparison
between the symptoms of the hydrated and non-hydrated groups
(Morita 2006).
Study design
Three studies had an RCT design (Bruera 2005; Bruera 2013;
Cerchietti 2000). The study intervention of these was for two
days (Bruera 2005; Cerchietti 2000) or “until the patient was
unresponsive, developedprogressive coma, or died” (Bruera 2013).
The other three studies had a prospective controlled trial design
(Morita 2005; Waller 1994; Viola 1997). The study conducted
in Japan by Morita 2005 had a study duration of three weeks,
while the study by Waller 1994 was from admission to a hospice
until death and Viola 1997 was from enrolment in the study until
death, discharge or no longer having a fluid deficit.
Study population
All of the studies included only participants with advanced cancer.
Four studies only included participants in whom it was thought
the participants were dehydrated (Bruera 2005; Bruera 2013;
Cerchietti 2000; Viola 1997).
Intervention
All of the studies aimed to administer at least 1000 mL of fluid per
day to the intervention group. The route of this varied between
intravenous and subcutaneous.
Outcomes
The outcomes measured in all the studies were very different.
• Waller 1994 only considered the state of consciousness.
• Bruera 2005 had a main outcome measure as the global
assessment of the overall benefit of hydration to the participant,
as determined by the physician and participant on day two. This
was supplemented by a number of secondary outcome measures.
These included symptom assessment scales used for sedation,
fatigue, hallucinations, myoclonus, symptoms totalled together
and the Mini Mental Status Examination (MMSE). These
symptoms were scored on a numerical rating of zero to 10 scale,
with a decrease of one point indicating an improvement (this was
defined by the authors and it is unclear whether this is a
statistical or clinical improvement).
• The RCT by Bruera 2013 had the primary outcome as the
change in the sum of four dehydration symptoms (fatigue,
myoclonus, sedation and hallucinations) between day four and
baseline. Secondary outcome measures included delirium
(Memorial Delirium Assessment Scale (MDAS), Richmond
Agitation Sedation Scale (RASS) Nursing Delirium Screening
Scale (NuDESC)), change in the sum of four dehydration
symptoms (fatigue, myoclonus, sedation and hallucinations)
between day seven and baseline, global symptom evaluation,
QoL using Functional Assessment of Chronic Illness Therapy -
Fatigue (FACIT-F) and Functional Assessment of Chronic
Illness Therapy - General (FACIT-G), hydration status using a
dehydration assessment scale and survival.
• Cerchietti 2000 primarily studied the symptoms of thirst,
chronic nausea, delirium and changes in MMSE. Secondary
outcome measures included anguish and mood.
• The observational study of Morita 2005 examined
dehydration, fluid retention (ascites, bronchial secretions,
peripheral oedema), hyperactive delirium, myoclonus, bedsores,
agitation and communication capacity.
• Viola 1997 studied the prevalence of multiple physical
symptoms and cognition.
• Two RCTS examined adverse effects of medically assisted
hydration including local adverse effects (discomfort, pain,
infection, oedema, erythema, bleeding at the puncture site) and
interruption of hydration due to adverse effects (oedema,
increase in respiratory secretions, congestive heart failure)
(Bruera 2005; Cerchietti 2000).
Risk of bias in included studies
All review authors assessed the included studies using two differ-
ent quality scales. We assessed the three RCTs using the Oxford
Quality Scale (Jadad 1996). Two of the RCTs scored five out of
five on this scale, as they were well-designed and well-performed
studies (Bruera 2005; Bruera 2013). In particular, the methods of
randomisation and blinding were well described and appropriate.
However, the third RCT scored only two out of five, as neither
the method of randomisation nor whether any blinding was per-
formed were described (Cerchietti 2000).
The other three studies were prospective controlled trials and we
assessed their quality using the Rinck scale (Rinck 1997). One of
the studies, Morita 2005, scored 4.5 out of a maximum of seven
on this scale. Its strengths were that consecutive participants were
asked to be enrolled and a good description of baseline character-
istics and follow-up was given. However, allocation was via physi-
cian preference, thus introducing an element of bias, and there
was no blinding of allocation to scoring of outcomes. The aim
of the allocation according to physician preference was to try to
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mimic real world decision making. The study by Waller 1994 was
subject to many methodological problems. There was inadequate
inclusion and recruitment strategy, a poorly defined control group,
no baseline data presented for groups, and the length of time and
composition of intravenous fluids was not included. This paper
scored 1.5 out of seven on the Rinck scale. The third prospective
study scored four out of seven on the Rinck scale (Viola 1997).
This study was well designed, but the major shortcoming was in
recruitment and performance of the study. Recruitment was per-
formed at two different centres, and the two groups at baseline had
many differences including type of cancers and symptom assess-
ment scores. This meant that we were unable to make a true com-
parison between the group receiving medically assisted hydration
and the control group receiving no medically assisted hydration
in any of the outcome measures.
For this update, we incorporated the Cochrane ’Risk of bias’
tool. The findings are listed in the ’Risk of bias’ table in the
Characteristics of included studies table. The overall findings are
presented in the ’Risk of bias’ graph (Figure 2) and the ’Risk of
bias’ summary (Figure 3). The two RCTs by Bruera et al. had a
low risk of bias (except for size of study) (Bruera 2005; Bruera
2013), while all the others had high or unclear risk across all the
categories.
Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Effects of interventions
Effectiveness
One study found that sedation and myoclonus were more greatly
improved in the intervention group (Bruera 2005). In addition,
if the total scores for the four target symptoms (sedation, fatigue,
hallucinations, myoclonus) were taken as a whole, there was more
improvement in the intervention group. The secondary outcome
measure used in the Bruera 2005 study (proportion of participants
perceived to have some benefit was 50% or greater) was signifi-
cant in the hydration group in the view of the physicians but not
the participant’s viewpoint. In another study (Cerchietti 2000), it
was stated that “control of chronic nausea after 24 hours was sig-
nificantly better in the group receiving hydration”. However, the
results were never tabulated, but rather presented in a graphical
form, and this actually showed the two groups almost equal after
24 hours, and the non-hydration group improving more than the
hydration group in terms of lowering the visual analogue score for
chronic nausea. One study found that night-time delirium was
worse in the control group compared with the hydration group at
day four, (but not day seven) as measured by NuDESC (Bruera
2013). There were no significant differences found in all the other
outcomes examined at in five other studies in terms of effective-
ness of medically assisted hydration (Bruera 2005; Bruera 2013;
Cerchietti 2000; Morita 2005; Waller 1994). The fifth study only
provided descriptive statistics, and so a comparison between the
groups was not possible (Viola 1997). In the one study that had
survival as an outcome measure, there was no difference between
the hydration and control groups (Bruera 2013).
Adverse events
In terms of local adverse reactions, Bruera 2005 reported no dif-
ferences between the groups, but Cerchietti 2000 found there was
one participant with erythema and pain at the puncture site in the
intervention group. Morita 2005 found that dehydration was sig-
nificantly higher in the non-hydration group, and that some fluid
retention symptoms (pleural effusion, peripheral oedema and as-
cites) were significantly higher in the hydration group.
D I S C U S S I O N
The objective of this systematic review was to determine the ef-
fect of medically assisted hydration in palliative care patients on
their QoL and length of life. Extensive searching of the literature
produced only six studies suitable for inclusion. This included
three RCTs. Two of these were of highmethodological quality, but
were unable to recruit a sufficient number of participants to ade-
quately power the studies (Bruera 2005; Bruera 2013), while the
other had methodological flaws in design and reporting of results
(Cerchietti 2000). One of these studies had survival as an outcome
and found no difference between the hydration and control arm
(Bruera 2013).Of the three prospective controlled studies, onewas
of reasonable quality (Morita 2005), while another had method-
ological shortcomings in design and reporting (Waller 1994). The
third prospectively controlled trial had a good methodological ba-
sis, but unfortunately, the two groups recruited had many differ-
ences at baseline (Viola 1997). There was also no statistical anal-
ysis of the results to determine if any differences were significant.
The participants included in these studies represent a ’narrow’ pal-
liative care population in that they all have cancer that is defined
as ’advanced’ or ’terminal’. It is questionable whether the results
of these studies would be generalisable to a wider palliative care
population, especially people who do not have cancer.
One study found that sedation and myoclonus (involuntary con-
tractions of muscles) scores were improved more in the interven-
tion group. Another study found that hydration may also cause
some adverse effects in terms of fluid retention (in particular pleu-
ral effusion, peripheral oedema and ascites). However, these results
must be taken within the context of low participant numbers and
methodological difficulties in the studies.
There has beenmuch debate and varying views about the provision
of medically assisted hydration to palliative care patients (Ashby
1995;Craig 1994;Dev2012;Raijmakers 2011). This review shows
that there have been very few high-quality studies examining the
symptom benefits, and adverse effects of such an intervention.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Since the last version of this review, we found one new study. The
studies published show no significant benefit in the use of medi-
cally assisted hydration in palliative care patients; however, there
are insufficient good quality studies to inform definitive recom-
mendations for practice with regard to the use of medically assisted
hydration in palliative care patients.
There are a few good-quality studies that examine the benefits and
harms of the use of medically assisted hydration in this population.
Two randomised controlled trials (RCTs) in this review had a
short duration of hydration (two days) to assess effects, and no
information on the effect hydration may have on survival. The
other RCT was of longer duration, and found little difference in
outcomes between the hydration and control groups. It also found
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no difference in survival between the two groups. The results from
one included study suggest that theremay be some benefit in terms
of improvement in sedation and myoclonus, but another study
showed that there may be some harm in terms of worsening of
fluid retention symptoms (pleural effusion, peripheral oedema and
ascites) and these results need to be taken in the context of low
participant numbers, limited palliative care settings and narrow
palliative care patient population groups. Clinicians will need to
make a decision based on the perceived benefits and harms of
medically assisted hydration in individual patient circumstances,
without the benefit of high-quality evidence to guide them.
Implications for research
Study design
High-quality studies in the palliative care population have proven
very difficult to perform successfully. The difficulty of research in
a vulnerable population such as palliative care patients has been
discussed in the literature. These difficulties start with consent,
are followed by recruitment, elimination of confounders and end
with retention of participants throughout a study period (Rinck
1997). There have been some innovative suggestions about how to
overcome the issue of consent (Rees 2003), and some studies have
used this methodology with success (Breitbart 2002). Other stud-
ies have shown that large numbers are not always needed to show a
benefit (Abernethy 2003), but the question of safety is difficult to
answer due to the small numbers of participants commonly being
found in palliative care studies. This has been illustrated by the
fact that there were only two RCTs of a high quality in this review.
Despite being methodologically sound, the results were limited by
lack of recruitment. Perhaps of more interest was that the issue
of medically assisted hydration in palliative care patients causes
such divergent views, yet there are so few studies to guide clinical
practice properly. As well as examining further RCTs in this area,
the evidence base will be improved with at least more prospective
controlled trials.
Participant groups
The studies in this review had narrowly defined patient popula-
tions. Palliative care is performed in hospitals, inpatient palliative
care units and in the community. Studies need to be performed in
all these areas to allow external validity to different palliative care
populations. It would also be helpful to define at what stage of
their illness participants are being given medically assisted hydra-
tion. The reasons and aims of hydration in the last few days/weeks
of life may be very different to those participants with a longer
prognosis. An agreed diagnostic criteria for hydration status is es-
sential for future trials, both to assess at entry and to assess as an
outcome. In addition, all the participants in the included studies
had advanced cancer, and it is important to examine medically as-
sisted hydration in non-cancer populations. The prospective pre-
diction of prognosis is difficult, and it may be better to stratify
participants according to their performance status.
Interventions
Medically assisted hydration canbe givenbymany different routes.
The studies included in this review used either the subcutaneous
or intravenous route. We found no studies that used the enteral
route for hydration. Further studies are needed to determine the
optimum route and dose.
Outcomes
It is important that clinically relevant outcomes are clearly defined
and are the most clinically useful. In this patient population, this
should include symptoms (such as sedation, fatigue, hallucinations
and myoclonus) as well as diagnoses such as delirium. Despite
much controversy about the effect medically assisted hydration
may have on length of life, it was only included as an outcome in
one study in this review. Future studies should include the survival
of participants as an outcome. It is equally important that adverse
events are well defined so that the risk of treatment can be balanced
against any benefits.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Bruera 2005
Methods Randomised, controlled, double-blind, multicentre trial
Method of randomisation: truly random
Study duration: 2 days
Participants Participantswith a diagnosis of advanced cancer, defined as locally recurrent ormetastatic,
with no further treatment planned
An oral intake < 1000 mL/day, as determined by clinical assessment; and evidence of
mild-to-moderate dehydration, exhibited by decreased turgor in the subclavicular region
lasting > 2 seconds
Participants had to have ≥ 1 of the following findings: dry mouth; thirst; decreased
volume of urine output, as reported by the patient; a darker colour of urine than usual,
in the absence of reasons for jaundice or haematuria; and laboratory values consistent
with dehydration, such as an elevated blood urea nitrogen to creatinine ratio of more
than 20:1, when this value was obtained within 24 hours of admission to the study
Participants had to be > 16 years, able to understand and give consent for participation in
the study, and able to tolerate parenteral treatment and the application of a subcutaneous
or IV cannula
Sample size: 74 (13 were not eligible, 10 refused)
51 recruited
Interventions 51 patients were randomised to 1 of 2 groups
1. Intervention: 1000 mL normal saline as an infusion over 4 hours for 2 days (28
recruited, 1 withdrawal)
2. Placebo: 100 mL normal saline as an infusion over 4 hours for 2 days (23
recruited, 1 withdrawal)
Route of administration: IV if IV access available (12 patients); subcutaneous if no IV
access (37 patients)
Outcomes Primary outcome was the global assessment of the overall benefit of hydration to the
participant, as determined by the physician and patient on day 2 - no statistically signif-
icant difference between groups
Secondarymethod of analysis was to test the 2 groups separately to determine whether the
proportion of patients perceived to have some benefit was 50% or > 50% - intervention
group - P value = 0.0035, placebo group - P value = 0.20
Target symptoms - numerical rating scale 0-10, with a decrease of 1 point seen as an
improvement
Sedation: more improvement in intervention group (P value = 0.005)
Fatigue: no difference between groups
Hallucinations: no difference between groups
Myoclonus: more improvement in intervention group (P value = 0.035)
Symptoms totalled together: more improvement in intervention group (P value = 0.06)
MMSE: no difference
Adverse effects: pain at injection site, injection site swelling: no differences between
groups
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Bruera 2005 (Continued)
Notes Oxford Quality Scale score: 5
Some differences in performance status at randomisation, with intervention group have
more participants in performance status 0, I and II
Study was underpowered, as recruitment was less than expected
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Random numbers”
Allocation concealment (selection bias) Low risk “Sealed envelopes”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Double blind”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blinding of outcome assessor
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants accounted for
Selective reporting (reporting bias) Low risk No problems detected
Size of Study (possible biases confounded
by small size)
High risk < 50 participants per treatment arm
Bruera 2013
Methods Randomised, placebo-controlled, double-blind, multicentre study
Method of randomisation: computer-generated simple randomisation scheme
Participants Advanced cancer (i.e. locally recurrent or metastatic disease) who were:
• aged ≥ 18 years
• admitted to hospice
• reduced oral intake of fluids with evidence of mild or moderate dehydration as
defined by:
◦ decreased skin turgor in subclavicular region (2 seconds) and
◦ score of ≥ 2 of 5 in the clinical dehydration assessment
• intensity of ≥ 1 on a 0 to 10 scale for fatigue and 2 of the 3 other target
symptoms (hallucinations, sedation and myoclonus)
• life expectancy 1 week
• availability of a primary carer
• MDAS score < 13
• ability to give written informed consent
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Bruera 2013 (Continued)
• geographic accessibility (within 60 miles of the University of Texas MD Anderson
Cancer Center)
Sample size: 905 patients assessed for eligibility
Excluded: 776
Included: 129
Interventions 129 patients were randomised to 1 of 2 groups
1. Parenteral hydration (1000 mL normal saline administered subcutaneously over 4
hours) (63 recruited, 49 completed and analysed)
2. Placebo (100 mL normal saline administered subcutaneously over 4 hours) (66
recruited, 53 completed and analysed)
Outcomes Primary outcome:
1. Change in the sum of 4 dehydration symptoms (fatigue, myoclonus, sedation and
hallucinations) between day 4 and baseline - no difference between groups
Secondary outcomes:
1. Delirium: MDAS - no difference, RASS - no difference, NuDESC - no
difference, except night-time NuDESC where placebo group deteriorated more than
intervention group (P value = 0.028)
2. Change in the sum of 4 dehydration symptoms (fatigue, myoclonus, sedation and
hallucinations) between day seven and baseline: no difference between groups
3. Global symptom evaluation: no difference between groups
4. Quality of life: day 7, using FACIT-F and FACIT-G: no difference between
groups
5. Hydration status: using dehydration assessment scale: no difference between
groups at day 4 and day 7
6. Survival: median survival 17 days, with no significant difference between groups
Notes Oxford Quality Scale score: 5
Underpowered - powered for 150 patients but recruitment stopped at 129 due to funding
limitations
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Computer-generated simple randomiza-
tion scheme”
Allocation concealment (selection bias) Low risk “Pharmacist randomly assigned patients”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Identical backpacks”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Research nurse conducting the study assess-
ments was blinded to study intervention
and randomisation sequence
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Bruera 2013 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants accounted for
Selective reporting (reporting bias) Low risk No problems detected
Size of Study (possible biases confounded
by small size)
Unclear risk 50-199 participants per treatment arm
Cerchietti 2000
Methods Randomised, comparative prospective, single-centre trial
Method of randomisation: unclear
Blinding status: unclear
Study duration: 48 hours
Participants Terminal stage advanced cancer patients.
≥ 1of the following symptoms: thirst; chronic nausea or delirium; dehydrationdiagnosed
on physical examination, with or without renal failure; and inability to maintain an
adequate water intake (< 50 mL/day fluid)
Sample size: 50
Exclusions: 4 uncontrolled symptoms (pain in 2 of the participants, severe dyspnoea in
2), 1 bowel obstruction syndrome requiring surgery, 3 severe constipation
Interventions 42 patients were randomised to 1 of 2 groups
1. Treatment (1000 mL 5% dextrose in water infusion with the addition of 140
mEq/L sodium chloride per day, at an infusion rate of 42 mL/hour subcutaneous (20
patients)
2. Usual treatment: no subcutaneous fluids given (22 patients)
Outcomes Primary outcomes (VAS):
1. Thirst
2. Chronic nausea
3. Delirium
4. MMSE
The results were not tabulated, and some graphs were given. The authors stated, “that
1000 ml/day subcutaneous hydration does not improve control of the assessed symptoms
when added to the general and pharmacological treatment in patients with end-stage
cancer. However, control of chronic nausea after 24 hours was significantly better in the
group receiving hydration”
However, the graph of this actually shows the 2 groups both improving and the non-
hydration group improving more in terms of the VAS
Secondary outcomes:
1. Anguish (measurement not defined): no differences between groups
2. Mood (measurement not defined): no differences between groups
3. Interruption of hydration (oedema, increase in respiratory secretions, congestive
heart failure)
4. Local adverse reactions: 1 patient had erythema and pain at puncture site, 36
hours after start of treatment
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Cerchietti 2000 (Continued)
Notes Oxford Quality Scale score: 2
Median survival: about 4 days in both groups
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk States “randomly assigned”, but method
not adequately described
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding described
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No blinding described
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Method not described
Selective reporting (reporting bias) Unclear risk Insufficient information
Size of Study (possible biases confounded
by small size)
High risk < 50 participants per treatment arm
Morita 2005
Methods Prospective, observational, multicentre study
Method of randomisation: none
Study duration: 3 weeks
Participants Age > 20 years; life expectancy estimated by a physician to be < 3 months; and incurable
malignancy of abdominal origin (excluding hepatic malignancies)
Sample size: 498 participants who met the inclusion criteria were consecutively recruited
for this study
Excluded: 272 participants for the following reasons: 200 death within 3 weeks of initial
assessment, 35 survival beyond the observation period, 17 medical complications, 15
prior communication difficulty, 5 discharged
Included: 226 patients (49 from oncology units and 177 from palliative/home-care
settings)
Interventions 226 patients were randomised to 1 of 2 groups
1. Hydration group (31 from oncology and 28 from palliative/home-care settings) -
patients who received artificial hydration of ≥ 1 L/day both 1 week and 3 weeks before
death (59 patients)
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Morita 2005 (Continued)
2. Non-hydration group (18 from oncology and 149 from palliative/home-care
settings) (167 patients)
The mean hydration volume in the hydration group was 838-1405 mL/day during the
last 3 weeks, and the median hydration volume in the non-hydration group was 200
mL/day at all 3 observation points
Form of hydration was unclear, but a previous paper described it as IV
Outcomes 1. Dehydration: significantly higher in the non-hydration group (35% versus 14%,
P value = 0.002)
2. Fluid retention:
i) pleural effusion: significantly higher in the hydration group (15% versus 5.
4%, P value = 0.016)
ii) ascites: significantly higher in the hydration group (29% versus 8.4%, P
value < 0.001)
iii) bronchial secretions: no significant difference between groups
iv) peripheral oedema: significantly higher in the hydration group (44% versus
29%, P value = 0.039)
3. Hyperactive delirium: no significant difference between groups
4. Myoclonus: no significant difference between groups
5. Bedsores: no significant difference between groups
6. Degree of communication capacity: no significant difference between groups
7. Degree of agitation between the 2 groups: no significant difference between groups
Notes Rinck score: 4.5
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Not randomised
Allocation concealment (selection bias) High risk Not randomised
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not blinded
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Not blinded
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Method not described
Selective reporting (reporting bias) Unclear risk Insufficient information
Size of Study (possible biases confounded
by small size)
Unclear risk 50-199 participants per treatment arm
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Viola 1997
Methods Prospective, comparative study
Multicentre study - Edmonton (hydration group) and Ottawa (no hydration group)
Method of randomisation: none
Study duration: enrolment until death, no longer having a fluid deficit or discharge from
palliative care unit
Participants Advanced cancer
Phase I: inpatients of either Edmonton or Ottawa palliative care units with advanced
cancer, not aphasic, MMSE > 24 and subjectively competent (as judged by physician),
able to understand English (Edmonton) or English or French (Ottawa)
Participant at risk of developing a fluid deficit or on admission already having a fluid
deficit:
• ’at risk’ defined as history of poor oral fluid intake or excess fluid loss or both
• ’fluid deficit’ was defined as being at risk for fluid deficit (as above) plus
◦ history of decreased urine output, dry mouth sensation, thirst sensation,
postural dizziness or combination or
◦ resting heart rate > 100 bpm, postural drop in blood pressure ≥ 10 mmHg
on sitting, poor skin turgor over sternum, dry mucous membranes, enophthalmos or
combination
Exclusions: receiving enteral tube feedings, acute renal failure, pulmonary oedema or
bleeding disorder, aphasic, MMSE < 24
Sample size: 288
Excluded: 165 (164 with cognitive deficit, 1 with bleeding disorder)
Consent sought: 123
Consented Phase I: 94
Considered for Phase II: 70
Entered Phase II: 68 (2 excluded as no data collected) leaving 66 participants
Interventions 66 patients were randomised to 1 of 2 groups
1. Edmonton group: subcutaneous fluids (titrated to participant needs) plus usual
care. Solutions were usually 0.9% saline or 0.3% saline with 3.3% dextrose.
Hyaluronidase 750 units added to each 1 L of fluid solution. The median volume was
approximately 1000 mL/day (- 33 patients)
2. Ottawa group: usual care (33 patients)
Outcomes VAS: 12 symptoms - pain, activity, nausea, depression, anxiety, drowsiness, appetite,
sense of well-being, dyspnoea, weakness, thirst and dry mouth Assessed by participants
or staff depending on ability of participants
Bowel movements
Vomiting
Pressure ulcers
Peripheral oedema
Myoclonus
Level of consciousness
Delirium Rating Scale
MMSE
Oral mucosal assessment
Time spent in Phase II and survival from enrolment in Phase II. The demographics of
the groups differed at study entry and there were also many differences in the outcome
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Viola 1997 (Continued)
measures at baseline. Results were only reported as frequency in each group, and there
was no statistical analysis performed to determine if there was any significant differences
between the groups on any of the measured outcomes
Notes Rinck score 4
Well-designed study, but the major flaw was that the groups were not matched at study
entry
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk No randomisation
Allocation concealment (selection bias) High risk Groups differed at study entry
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No blinding
Incomplete outcome data (attrition bias)
All outcomes
High risk As treated analysis
Selective reporting (reporting bias) Unclear risk Not described
Size of Study (possible biases confounded
by small size)
High risk < 50 participants per treatment arm
Waller 1994
Methods Prospective controlled, single centre study
Method of randomisation: none
Study duration: admission to hospice until death
Participants Palliative care patients admitted to hospice, in whom blood and urine samples were
collected ≤ 48 hours before death
Interventions 68 patients were randomised to 1 of 2 groups
1. Oral hydration: volumes not described (55 patients)
2. IV hydration: 1-2 L/day (13 patients)
Outcomes State of consciousness: no significant difference between groups
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Waller 1994 (Continued)
Notes Rinck score = 1.5
Methodological problems:
• Poorly defined control group
• No baseline data presented
• Length of time of IV fluids not stated
• Nature of IV fluid not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Not randomised
Allocation concealment (selection bias) High risk Not randomised
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not blinded
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Not blinded
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not stated
Selective reporting (reporting bias) Unclear risk Insufficient information
Size of Study (possible biases confounded
by small size)
High risk < 50 participants per treatment arm
bpm: beats per minute; FACIT-F: Functional Assessment of Chronic Illness Therapy - Fatigue; FACIT-G: Functional Assessment
of Chronic Illness Therapy - General; IV: intravenous; MDAS: Memorial Delirium Assessment Scale; MMSE: Mini Mental State
Examination; NuDESC: Nursing Delirium Screening Scale; RASS: Richmond Agitation Sedation Scale; VAS: visual analogue scale.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Morita 2002 Prospective controlled study examining fluid status of terminally ill cancer patients with intestinal obstruction.
Excluded because there was no comparisons between groups with regards to hydration
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(Continued)
Morita 2006 Multicentre, prospective, observational study examining artificial hydration therapy, laboratory findings and fluid
balance in terminally ill patients with abdominal malignancies. Excluded because there was no comparison between
the symptoms of the hydrated and non-hydrated groups
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D A T A A N D A N A L Y S E S
This review has no analyses.
A P P E N D I C E S
Appendix 1. Search strategies for 2014 update
CENTRAL (The Cochrane Library)
#1 MeSH descriptor: [Palliative Care] explode all trees
#2 palliat*:it,ab,kw (Word variations have been searched)
#3 MeSH descriptor: [Terminally Ill] this term only
#4 MeSH descriptor: [Terminal Care] explode all trees
#5 (terminal* near/6 care*):it,ab,kw (Word variations have been searched)
#6 ((terminal* near/6 ill*) or terminal-stage* or dying or (close near/6 death)):it,ab,kw (Word variations have been searched)
#7 (terminal* near/6 disease*):it,ab,kw (Word variations have been searched)
#8 (end near/6 life):it,ab,kw (Word variations have been searched)
#9 hospice*:it,ab,kw (Word variations have been searched)
#10 (“end-stage disease*” or “end stage disease* or end-stage illness” or “end stage”):it,ab,kw (Word variations have been searched)
#11 “advanced disease*”:it,ab,kw (Word variations have been searched)
#12 (“incurable illness*” or “incurable disease*”):it,ab,kw (Word variations have been searched)
#13 (“advanced directive*” or “living will*” or “do-not-resuscitate order*”):it,ab,kw (Word variations have been searched)
#14 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13
#15 MeSH descriptor: [Fluid Therapy] this term only
#16 MeSH descriptor: [Dehydration] this term only
#17 (hydrat* or dehydrat* or rehydrat* or (fluid* near/6 therap*) or (fluid* near/6 balance*) or (fluid* near/6 manag*) or hypodermo-
clysis):it,ab,kw (Word variations have been searched)
#18 #15 or #16 or #17
MEDLINE (Ovid)
1 exp Palliative Care/
2 palliat*.tw.
3 Terminally Ill/
4 Terminal Care/
5 (terminal* adj6 care*).tw.
6 ((terminal* adj6 ill*) or terminal-stage* or dying or (close adj6 death)).tw.
7 (terminal* adj6 disease*).tw.
8 (end adj6 life).tw.
9 hospice*.tw.
10 (“end-stage disease*” or “end stage disease* or end-stage illness” or “end stage”).tw.
11 “advanced disease*”.tw.
12 (“incurable illness*” or “incurable disease*”).tw.
13 (“advanced directive*” or “living will*” or “do-not-resuscitate order* ”).tw.
14 or/1-13
15 Fluid Therapy/
16 Dehydration/ (9949)
17 (hydrat* or dehydrat* or rehydrat* or (fluid* adj6 therap*) or (fluid* adj6 balance*) or (fluid* adj6 manag*) or hypodermoclysis).tw.
18 15 or 16 or 17
19 14 and 18
20 (2010* or 2011* or 2012* or 2013* or 2014*).ed.
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21 19 and 20
EMBASE (Ovid)
1 exp Palliative Care/
2 palliat*.tw.
3 Terminally Ill/
4 Terminal Care/
5 (terminal* adj6 care*).tw.
6 ((terminal* adj6 ill*) or terminal-stage* or dying or (close adj6 death)).tw.
7 (terminal* adj6 disease*).tw.
8 (end adj6 life).tw.
9 hospice*.tw.
10 (“end-stage disease*” or “end stage disease* or end-stage illness” or “end stage”).tw.
11 “advanced disease*”.tw.
12 (“incurable illness*” or “incurable disease*”).tw.
13 (“advanced directive*” or “living will*” or “do-not-resuscitate order* ”).tw.
14 or/1-13
15 Fluid Therapy/
16 Dehydration/
17 (hydrat* or dehydrat* or rehydrat* or (fluid* adj6 therap*) or (fluid* adj6 balance*) or (fluid* adj6 manag*) or hypodermoclysis).tw.
18 15 or 16 or 17
19 14 and 18
20 (2010* or 2011* or 2012* or 2013* or 2014*).dd.
21 19 and 20
Science Citation Index (ISI Web of Science)
# 13 295 #12 AND #11
# 12 53,258 Topic=((hydrat* or dehydrat* or rehydrat* or (fluid* near/6 therap*) or (fluid* near/6 balance* ) or (fluid* near/6 manag*
) or hypodermoclysis))
# 11 37,433 #10 OR #9 OR #8 OR #7 OR #6 OR #5 OR #4 OR #3 OR #2 OR #1
# 10 386 Topic=((“advanced directive*” or “living will*” or “do-not-resuscitate order*”))
# 9 412 Topic=((“incurable illness*” or “incurable disease*”))
# 8 3,316 Topic=(“advanced disease*”)
# 7 12,963 Topic=((“end-stage disease*” or “end stage disease* or end-stage illness” or “end stage”))
# 6 2,135 Topic=(hospice*)
# 5 6,392 Topic=((end near/3 life))
# 4 1,176 Topic=((terminal* near/6 disease*))
# 3 1,527 Topic=((terminal* near/6 ill*))
# 2 906 Topic=((terminal* near/6 care*))
# 1 14,889 Topic=(palliat*)
CINAHL (EBSCO)
S23 S14 AND S22
S22 S15 OR S16 OR S17 OR S18 OR S19 OR S21
S21 (fluid* N6 manag* )
S20 (fluid* N6 balance* )
S19 (fluid* N6 therap*)
S18 hypodermoclysis
S17 (hydrat* or dehydrat* or rehydrat*)
S16 (MH “Dehydration”)
S15 (MH “Fluid Therapy”)
S14 S1 OR S2 OR S3 OR S4 OR S5 OR S6 OR S7 OR S8 OR S9 OR S10 OR S11 OR S12 OR S13
S13 (“advanced directive*” or “living will*” or “do-not-resuscitate order*”)
S12 (“incurable illness*” or “incurable disease*”)
S11 “advanced disease*”
S10 (“end-stage disease*” or “end stage disease* or end-stage illness” or “end stage”)
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S9 hospice*
S8 (end n3 life)
S7 (terminal* N6 disease*)
S6 (terminal* N6 ill*)
S5 (terminal* N6 care*)
S4 (MH “Terminal Care+”)
S3 (MH “Terminally Ill Patients+”)
S2 palliat*
S1 (MH “Palliative Care”)
WH A T ’ S N E W
Last assessed as up-to-date: 26 March 2014.
Date Event Description
8 May 2015 Review declared as stable This review will be assessed for further updating in 2019.
H I S T O R Y
Protocol first published: Issue 4, 2006
Review first published: Issue 2, 2008
Date Event Description
16 April 2014 New citation required and conclusions have changed The search for this review was re-run in April 2013
and March 2014. No new studies were found. Minor
change to conclusions. We recommend that readers of
the original review read this latest version
9 January 2014 New search has been performed We added a PRISMA flowchart to document the study
selection process and added risk of bias tables
14 February 2011 New search has been performed The search for this review was re-run in February 2011.
No new studies were identified to be included in this
review
6 October 2010 Amended Contact details updated.
6 August 2008 Amended Converted to new review format.
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